A team of researchers from the University of Osaka found that cells producing IgG1 antibodies have advantages over those producing IgM antibodies, including better antigen presentation, survival, and bone marrow migration. These advantages may lead to long-term immune protection and inform the development of more effective vaccines.
A new study suggests that HLA-II peptide-binding diversity influences antibody responses and susceptibility to infections. Individuals with broader peptide-binding repertoires were more likely to show antibody responses and had a lower risk of severe infections requiring hospital care.
A novel vaccination approach cleared harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. The experimental vaccine protected against illness, death, tissue damage and infection recurrence through mucosal immunization.
Physicians from Ruhr-University Bochum used CAR T-cell therapy to treat two patients with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disease causing paralysis and loss of sensation. The treatment showed rapid and long-lasting effects, with significant improvements in symptoms and functional abilities.
Patients with 18q deletion syndrome exhibit both cellular and humoral immunodeficiency, characterized by low immunoglobulin levels and impaired T-cell function. Regular testing for both cellular and humoral immunity can allow for early detection of combined immune deficiencies and improve clinical outcomes.
A new study found that high-dose influenza vaccine significantly improved humoral response in patients with heart failure or prior myocardial infarction. Vaccination remains crucial in preventing influenza-related complications in high-risk populations.
A recent study published in the Journal of Clinical Immunology suggests that cutaquig infusions at higher infusion rates and volumes are well-tolerated and effective, with reduced infusion time, fewer injection sites, and improved compliance. The study results will be presented at the Clinical Immunology Society 2023 Annual Meeting.
A team from Osaka University discovered that celastrol blocks the progression of rheumatoid arthritis by inhibiting a protein complex that promotes autoimmune responses. The researchers found that celestrol binds to COMMD3 covalently, preventing the formation of the COMMD3/8 complex and impairing antibody production.
Researchers at Osaka University found that male patients with COVID-19 have a faster loss of circulating Treg cells, leading to dysregulated antibody responses. Females, on the other hand, have higher levels of these cells, which may help protect them from infection.
A high-fat diet allows the immune system to eliminate a parasitic worm that causes long-lasting infections in the large intestine. This discovery may lead to new treatments for millions suffering from intestinal parasitic infections worldwide.
Boosting with either Janssen or Pfizer-BioNTech vaccine boosts humoral and cellular immune responses. Boosting with Janssen vaccine provides durable antibody and T-cell responses for at least four months.
Researchers identified two types of humoral immune responses in PTCs, one effective in controlling short episodes of viral activity and another lacking strong response. This discovery sheds light on HIV control mechanisms and could inspire novel therapeutic or vaccine strategies.
A team of researchers developed a new nanomechanical technique to fast-track the detection of COVID-19 variants. The method provides real-time insights into infection immunity and enables direct classification of variant-binding properties.
A study published in Immunity identified five humoral immune response markers that can correctly classify convalescent COVID-19 patients and those who did not survive the disease. These markers, including IgM and IgA1 responses to S protein and N protein, were able to predict patient outcomes more accurately than demographic factors.